Vanda Pharmaceuticals (LTS:0LKB) Interest Income: $0.0 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0LKB Vanda Pharmaceuticals Inc LTS:0LKB
63 GF Score
Price $5.36
GF Value $5.40
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Vanda Pharmaceuticals Interest Income?

Vanda Pharmaceuticals LTS:0LKB +1.87% 63 Interest Income is $0.0 Mil as of Jun. 2026. GuruFocus rates LTS:0LKB with a GF Score™ of 63/100 and a GF Value™ of $5.40 (Fairly Valued). The stock has 4 warning signs investors should review.

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments. Vanda Pharmaceuticals's interest income for the three months ended in Jun. 2026 was $0.0 Mil. Its interest income for the trailing twelve months (TTM) ended in Jun. 2026 was $0.0 Mil.

Vanda Pharmaceuticals Interest Income Historical Data

* Premium members only.

The historical data trend for Vanda Pharmaceuticals's Interest Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vanda Pharmaceuticals Interest Income Chart

Vanda Pharmaceuticals Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Vanda Pharmaceuticals Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Interest Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LTS:0LKB
63GF Score
Vanda Pharmaceuticals Inc LTS:0LKB
Interest Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Vanda Pharmaceuticals Interest Income Calculation

Interest Income is the interest earned on cash temporarily held in savings accounts, certificates of deposits, or other investments.

Interest Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Income →
What does a Interest Income of $0.0 Mil mean?
Vanda Pharmaceuticals (LTS:0LKB) has a Interest Income of $0.0 Mil as of Jun. 2026. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on Vanda Pharmaceuticals and its competitors.
Is Vanda Pharmaceuticals' Interest Income too high?
Vanda Pharmaceuticals' current Interest Income is $0.0 Mil. Overall, Vanda Pharmaceuticals has a GF Score™ of 63/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vanda Pharmaceuticals' Interest Income compare to IMRX and PRQR?
Vanda Pharmaceuticals' Interest Income of $0.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Income for a Biotechnology company?
A good Interest Income depends on the Biotechnology industry context. However, Interest Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Income mean?
A high Interest Income can signal that a stock is expensive relative to its fundamentals. Interest Income is the amount a company receives on savings accounts and certificates of deposits. View historical data on Vanda Pharmaceuticals and its competitors. Vanda Pharmaceuticals's current Interest Income is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vanda Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Vanda Pharmaceuticals (LTS:0LKB) is currently considered Fairly Valued. The stock's GF Value™ is $5.40, compared to a current price of $5.36 — trading 0.8% below its estimated fair value. The current Interest Income is $0.0 Mil. Vanda Pharmaceuticals' overall GF Score™ is 63/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Income calculated?
Interest Income is calculated from a company's financial statements. For Vanda Pharmaceuticals (LTS:0LKB), the current Interest Income is $0.0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Vanda Pharmaceuticals (LTS:0LKB) Overvalued in 2026?

Based on GuruFocus' analysis, Vanda Pharmaceuticals stock appears to be undervalued. The current stock price of $5.36 is trading 0.8% below its estimated GF Value™ of $5.40. GuruFocus considers Vanda Pharmaceuticals to be Fairly Valued.

Key valuation signals for LTS:0LKB:

  • Interest Income: $0.0 Mil
  • GF Value™: $5.40 vs. price of $5.36 (0.8% below fair value)
  • GF Score™: 63/100 with 4 warning signs

No single metric tells the full story. See the LTS:0LKB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vanda Pharmaceuticals Business Description

Other Exchanges VNDA:USAVM4:Germany
Address 2200 Pennsylvania Avenue North West, Suite 300 E, Washington, DC, USA, 20037
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include ASO Molecules, VQW-765, Tradipitant, and VTR-297. The maximum of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
63GF Score

Get the complete analysis for LTS:0LKB

Interest Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.36
Price
$5.40
GF Value